Last updated: February 9, 2026
Case Overview
Eisai Co., Ltd. filed a patent infringement suit against Lupin Limited in the District of Delaware. The case number is 1:19-cv-01336. The dispute centers on a patent related to an anti-epileptic drug formulation.
Key Details
- Plaintiff: Eisai Co., Ltd.
- Defendant: Lupin Limited
- Filed Date: May 20, 2019
- Jurisdiction: District of Delaware
- Patent: U.S. Patent No. 9,026,968 (claimed) on a formulation for epilepsy treatment
- Allegation: Lupin's generic version infringes on Eisai’s patent by marketing a competing formulation.
Patents at Issue
Eisai’s patent covers a specific oral sustained-release formulation containing the active ingredient levetiracetam, used for epilepsy management. The patent claims focus on the composition, including specific excipients and release mechanisms designed to optimize absorption and reduce side effects.
Infringement Claims
Eisai alleges that Lupin manufactured, marketed, or sold a generic version that directly infringes the patent's claims. The complaint emphasizes differences in formulation, but asserts that Lupin's product falls within the patent's scope.
Legal Proceedings & Developments
- Initial Complaint: Filed May 2019, seeking injunctive relief and damages.
- Lupin's Response: Denied infringement, challenged the validity of the patent via AIA post-issuance proceedings.
- District Court Proceedings: The court initially scheduled a Markman hearing to interpret patent claims.
Claim Construction
The court focused on terms such as "sustained-release," "controlled-release," and specific excipient ratios. The interpretation of "sustained-release" as a time-dependent release mechanism was central, with Lupin arguing for broader claim scope.
Summary Judgment & Motions
- The parties filed motions for summary judgment on infringement and validity.
- Eisai requested a preliminary injunction, citing the threat of irreparable harm and the patent's presumed validity.
Relevance of Inter Partes Review (IPR)
Lupin initiated IPR proceedings against the '968 patent, challenging its validity with prior art references, including prior publications and product disclosures.
- The Patent Trial and Appeal Board (PTAB) issued a final decision, invalidating all challenged claims in 2021.
- This ruling could significantly impact the infringement case, as patent validity is a prerequisite for infringement.
Outcome & Status
As of the latest update, the litigation remains active. The district court determined that the IPR's final decision on patent validity must be incorporated into the infringement analysis. The case may proceed to trial, depending on the district court's findings and whether the patent survives or is invalidated.
Implications
- The invalidation by PTAB introduces a major challenge for Eisai.
- If the patent is declared invalid, Lupin can market its generic without infringement liability.
- The case exemplifies the impact of inter partes review on patent litigation strategies in pharmaceutical IP cases.
Key Takeaways
- Patent validity determined through IPR significantly affects infringement claims.
- Claim construction regarding "sustained-release" plays a critical role in litigation.
- District courts consider PTAB’s final decisions in infringement proceedings.
- Patent litigation involving generics frequently involves concurrent patent validity challenges.
- The outcome hinges on whether the patent withstands invalidity claims in IPR and the district court.
FAQs
-
What is the significance of IPR proceedings in patent litigation?
They enable challengers to disputes validity prior to or during infringement litigation, often leading to invalidation of patent claims, influencing the infringement case outcome.
-
How does claim construction impact patent infringement suits?
It defines the scope of patent claims, determining whether a defendant's product infringes based on the interpretation of key terms.
-
What role does the district court play after a PTAB invalidation decision?
The district court can consider PTAB’s findings as evidence and may dismiss infringement claims if the patent claims are deemed invalid.
-
Can a patent's invalidation nullify ongoing infringement litigation?
Yes. If the patent is invalidated, the infringement claim typically fails because infringement requires a valid patent.
-
What are the strategic implications for a patent holder in such cases?
Patent holders must defend validity vigorously, including challenging prior art references, and consider the impact of IPR proceedings on their patent rights.
Citations
[1] Federal Court filings for Eisai Co., Ltd. v. Lupin Limited, District of Delaware, Case No. 1:19-cv-01336.
